TickerFacts.

Kalaris Therapeutics, Inc. (KLRS): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$38.57M
Year ended 2025-12-31
2019-12-31: -$20.49M2020-12-31: -$61.05M2021-12-31: -$106.34M2025-12-31: -$38.57M-$38.57M
2019-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$38.57Mn/a2026-03-17, From 2025-01-01
No annual figure between 2021-12-31 and 2025-12-31.
2021-12-31-$106.34Mn/m2023-02-15, From 2021-01-01
2020-12-31-$61.05Mn/m2022-02-10, From 2020-01-01
2019-12-31-$20.49Mn/a2021-02-12, From 2019-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Kalaris Therapeutics, Inc. (KLRS)2025-12-31-$38.57Mn/a
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31-$115.63Mn/m
Candel Therapeutics, Inc. (CADL)2025-12-31-$38.90Mn/m
Humacyte, Inc. (HUMA)2025-12-31-$105.93Mn/m
Zura Bio Ltd (ZURA)2025-12-31-$64.93Mn/m
Pelthos Therapeutics Inc. (PTHS)2025-12-31-$22.69Mn/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31-$79.34Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$19.44Mn/m
Palisade Bio, Inc. (PALI)2024-12-31-$12.19Mn/m

Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗